Molecular Epidemiology of Acute Myelogenous Leukemia
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/16/2018 |
| Start Date: | September 2003 |
| End Date: | September 2019 |
Little is known about the epidemiologic risk factors associated with the development of acute
myelogenous leukemia (AML), and less is known about the role that genetic susceptibility
plays in the development of AML. We propose to conduct a population-based study to
investigate genetic susceptibility in adult AML patients, both de novo and treatment-related
in a well-defined geographical area. Using a case-control design, we will prospectively
enroll 400 patients from Texas and 800 healthy controls. Controls will be recruited using
random digit dialing, and will be matched to the cases by age, gender, and ethnicity.
Epidemiological and demographic information will be obtained through personal interviews, and
will be integrated with clinical information, cytogenetic data, and genotypic markers. Blood
specimens will be collected on all participants, who will be genotyped for markers associated
with activation and detoxification of chemical carcinogens, including chemotherapy drugs.
Polymorphisms in genes such as cytochrome p450 (CYP2E1), glutathione S-transferases (GSTT1,
GSTM1, GSTP1), epoxide hydrolase (HYL1), NADPH-quinone oxidoreductase (NQO1), and
myeloperoxidase (MPO) will be analyzed.
This study will provide insight into the role that these susceptibility markers, along with
clinical epidemiological, and cytogenetic factors, play in the identification of people at
risk of developing AML. Understanding how genetic predisposition and exogenous exposures
interact to determine AML susceptibility will allow the development of prevention strategies
in the future.
myelogenous leukemia (AML), and less is known about the role that genetic susceptibility
plays in the development of AML. We propose to conduct a population-based study to
investigate genetic susceptibility in adult AML patients, both de novo and treatment-related
in a well-defined geographical area. Using a case-control design, we will prospectively
enroll 400 patients from Texas and 800 healthy controls. Controls will be recruited using
random digit dialing, and will be matched to the cases by age, gender, and ethnicity.
Epidemiological and demographic information will be obtained through personal interviews, and
will be integrated with clinical information, cytogenetic data, and genotypic markers. Blood
specimens will be collected on all participants, who will be genotyped for markers associated
with activation and detoxification of chemical carcinogens, including chemotherapy drugs.
Polymorphisms in genes such as cytochrome p450 (CYP2E1), glutathione S-transferases (GSTT1,
GSTM1, GSTP1), epoxide hydrolase (HYL1), NADPH-quinone oxidoreductase (NQO1), and
myeloperoxidase (MPO) will be analyzed.
This study will provide insight into the role that these susceptibility markers, along with
clinical epidemiological, and cytogenetic factors, play in the identification of people at
risk of developing AML. Understanding how genetic predisposition and exogenous exposures
interact to determine AML susceptibility will allow the development of prevention strategies
in the future.
INFORMED CONSENTS FOR AML PATIENTS:
For this study, participant will be asked to complete a personal interview. During the
interview, participant will be asked questions about participant's demographics (age, sex,
etc.), any chemicals participant may have been exposed to, participant's medical history,
family history of cancer, participant's diet, and participant's smoking and alcohol use
histories. It should take around 50 minutes to complete the interview.
Participant will also have around 1 tablespoon of blood drawn for special tests. These tests
will look for any biologic factors associated with AML.
The interview and the blood draw may be done during a regularly scheduled visit to M. D.
Anderson, or may be scheduled at the time and place of participant's convenience.
Participant may be contacted at home by phone so that researchers can collect information
about any changes in participant's health status.
This is an investigational study. Up to 1,200 participants will take part in this study.
INFORMED CONSENT FOR CONTROL SUBJECTS:
For this study, participant will be asked to complete a personal interview. During the
interview, participant will be asked questions about participant's demographics (age, sex,
etc.), any chemicals participant may have been exposed to, participant's medical history,
family history of cancer, participant's diet, and participant's smoking and alcohol use
histories. It should take around 50 minutes to complete the interview.
Participant will also have around 1 tablespoon of blood drawn for special tests. These tests
will look for any biologic factors associated with AML. The interview and blood draw will be
scheduled at the time and place of participant's convenience.
This is an investigational study. Up to 1,200 participants will take part in this study.
For this study, participant will be asked to complete a personal interview. During the
interview, participant will be asked questions about participant's demographics (age, sex,
etc.), any chemicals participant may have been exposed to, participant's medical history,
family history of cancer, participant's diet, and participant's smoking and alcohol use
histories. It should take around 50 minutes to complete the interview.
Participant will also have around 1 tablespoon of blood drawn for special tests. These tests
will look for any biologic factors associated with AML.
The interview and the blood draw may be done during a regularly scheduled visit to M. D.
Anderson, or may be scheduled at the time and place of participant's convenience.
Participant may be contacted at home by phone so that researchers can collect information
about any changes in participant's health status.
This is an investigational study. Up to 1,200 participants will take part in this study.
INFORMED CONSENT FOR CONTROL SUBJECTS:
For this study, participant will be asked to complete a personal interview. During the
interview, participant will be asked questions about participant's demographics (age, sex,
etc.), any chemicals participant may have been exposed to, participant's medical history,
family history of cancer, participant's diet, and participant's smoking and alcohol use
histories. It should take around 50 minutes to complete the interview.
Participant will also have around 1 tablespoon of blood drawn for special tests. These tests
will look for any biologic factors associated with AML. The interview and blood draw will be
scheduled at the time and place of participant's convenience.
This is an investigational study. Up to 1,200 participants will take part in this study.
Inclusion Criteria:
1. A histologically confirmed diagnosis of AML (patients only)
2. Aged 18 or older
3. Resident of Texas
4. Willing and able to provide written informed consent and authorization
5. Willing to donate 10mL of blood and complete a personal interview
Exclusion Criteria:
1. Under 18 years of age
2. History of invasive cancer, excluding non-melanoma skin cancer (controls only)
We found this trial at
1
site
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
